Bentley Pharmaceuticals (BNT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Bentley Pharmaceuticals (BNT)

BNT 46.81

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Roger Greene who wrote ()	1/4/1998 3:03:00 AM
From: Robert Williams	Read Replies (1) of 17

Roger, Your analysis appears right on target. The company certainly seems undervalued when compared with its peers in the pharmaceutical industry. A clear indication of the growing recognition for developments that are underway is the increase in institutional and insider investment. A recent edgar filing indicates that Dreyfuss (of the Dreyfus family of mutual funds) has purchased more than 5% of the outstanding stock in the last few months. In addition, another filing states that Michael McGovern, a new appointee to Bentley's board of directors, has also acquired approximately 10% of the outstanding shares. The press release that accompanied the filing suggested that McGovern's credentials are impeccable. It stated that he is a CPA as well an attorney and that he sits on several other boards. It would seem only a matter of time before Bentley becomes more properly valued. Best Regards, Robert Williams

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext